Patent intelligence · US
US 6028103
Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation
Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by a…
Patent details — US 6028103
- Jurisdiction
- US
- Status
- expired
- Grant date
- Feb 22, 2000
- Expiration
- Feb 17, 2020
- Applicant
- Ion Pharmaceuticals, Inc.
- Claims
- 42
- CPC classes
- A61P, A61P35/00, A61P43/00
Quick answer
US 6028103 (Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation) is held by Ion Pharmaceuticals, Inc.. Status: expired. Granted Feb 22, 2000. Expires Feb 17, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Ion Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 42
- CPC classes
- A61P, A61P35/00, A61P43/00
More from Ion Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 6028103?
US 6028103 (Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation) is held by Ion Pharmaceuticals, Inc.. Status: expired. Granted Feb 22, 2000. Expires Feb 17, 2020 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6028103?
Ion Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 6028103 expire?
Our index shows an expiration date of Feb 17, 2020 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.